Finding the needle in the haystack: Why high-throughput screening is good for your health

Breast Cancer Research

Volumn 4, Issue 4, 2002, Pages 148-154

  Aheme, G Wynne ^a   McDonald, Edward ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemistry; Drug discovery; High throughput screening; New molecular targets

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CYTOTOXIC AGENT; GEFITINIB; IMATINIB; LONAFARNIB; PHOSPHOTRANSFERASE INHIBITOR; ROSCOVITINE; SEMAXANIB; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RESEARCH; CONTROLLED STUDY; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; MEDICAL GENETICS; MEDICAL TECHNOLOGY; MOLECULAR GENETICS; MOLECULAR WEIGHT; SCREENING TEST;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; GENOMICS; GROWTH INHIBITORS; HUMAN GENOME PROJECT; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN KINASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036041930     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr440     Document Type: Article

References (53)

1. Initial sequencing and analysis of the human genome
2. The sequence of the human genome
3. Cancer and genomics
4. Cancer genetics
5. Scoring a bulls-eye against cancer genome targets
6. Changing times: Developing cancer drugs in genomeland
7. Mechanism-based target identification and drug discovery in cancer research
8. Translating basic cancer research into new cancer therapies
9. Mechanism-based high throughput screening for novel anticancer drug discovery
10. Drugs and pharmaceutical sciences
11. The in silico world of virtual libraries
12. Discovery of small molecule inhibitors of Bcl-2 through structure based computer screening
13. High-throughput and ultra-high-throughput screening: Solution and cell-based approaches
14. Chemiluminescent reporter gene assays with 1,2-dioxetane enzyme substrates
15. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications
16. Cell based assays for identification of novel double strand break inducing agents
17. Use of isogenic human cancer cells for high-throughput screening and drug discovery
18. Chemical genetic approaches for the elucidation of signaling pathways
19. Molecular targets in cancer drug discovery: Cell based profiling
20. A simple statistical parameter for use in evaluation and validation of high throughput screening assays
21. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting
22. Reactive compounds and in vitro false positives in HTS
23. ZD1839 ('Iressa') as an anticancer agent
24. ST1571 (Gleevec) as a paradigm for cancer therapy
25. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularisation, and growth of multiple tumor types
26. Unravelling the complexities of the Raf-MAP kinase pathway for pharmacological intervention
27. Discovery of a novel Raf kinase inhibitor
28. Assay and expression of mitogen-activated protein kinase, MAP kinase kinase and Raf
29. Blockade of the MAP kinase pathway suppresses growth of colon tumours in vivo
30. Identification of a novel inhibitor of mitogen-activated protein kinase
31. Pharmacological rescue of mutant p53 conformation and function
32. Therapeutic exploration of the p53 pathway
33. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
34. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
35. Negative regulators of cyclin-dependent kinases and their roles in cancers
36. Radiosensitisation of mutant cells by PD0166285, a novel G2 checkpoint abrogator
37. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen
38. Inhibition of tumour cell invasion and angiogenesis by motuporamines
39. Cyclins and breast cancer
40. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers
41. HSP90 as a new therapeutic target for cancer therapy: The story unfolds
42. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
43. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
44. HIF-1 and tumour progression: Pathophysiology and therapeutics
45. Histone acetylation modifiers the pathogenesis of malignant disease
46. High throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (flashplate)
47. Update on Her-2 as a target for cancer therapy: Herceptin in the clinical setting
48. Preclinical antitumour activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
49. Farnesyl transferase inhibitors - A novel targeted therapy for breast cancer
50. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
51. Aromatase inhibitors continue their ATAC on tamoxifen
52. Innovation in the pharmaceutical industry